The Chinese New Year is approaching, the second "CLEAP China Liver Cancer Study Group Young Investigators" forum was held grandly in Shanghai recently. The CLEAP collaborative group gathers elite talents from national high-level liver cancer diagnosis and treatment centers, aiming to jointly create multi-center clinical research that meets international standards. This forum advocates for both clinical and scientific research, focusing on clinical hotspots, exploring scientific research progress, and analyzing the forefront of the industry; Building platforms, discussing scientific research, seeking innovation, and promoting development, leading the new trend of "Chinese scientific research", and helping to promote the level of liver cancer research in China to a new level.

Due to the contributions made to the construction and development of the CLEAP group, Dunwill Medical was awarded the "CLEAP Co-construction Award". Ms. Sofia Wen, founder and CEO of Dunwill Medical, went on the stage as a company representative and accepted the award.

In today's environment, technological change and cross-border integration are accelerating, and the emergence of innovative technologies and therapies has put forward higher standards for researchers and pharmaceutical companies in the field of liver cancer. During the meeting, Ms. Wen was invited to participate in a roundtable forum with the theme of "Development Trends in Medical Research under the Background of Original Innovation". She shared her views and insights on the current field of scientific research innovation, as well as her profound insights and insightful insights on scientific research development trends, which were highly recognized by experts and scholars present. Through the integration of medicine, enterprises, and research, we can achieve steady progress in the face of major changes.

The development of liver cancer diagnosis and treatment in China requires young and middle-aged researchers, enterprise R&D personnel, and clinical research experts to solve core and difficult problems. Only through the unity and cooperation of medicine, academia, research, industry, and government can China's level of liver cancer diagnosis and treatment be continuously improved, allowing China to truly dominate in the field of liver cancer diagnosis and treatment, and benefiting the vast number of liver cancer patients. CLEAP uses the experience of mature collaborative research models and relies on a standardized, innovative, and intelligent clinical research system. We believe that it will also contribute to the efficient achievement of the great goal of "Healthy China 2030" in the future.